New to Magnet.me? Sign up now to get your own personalised job matches.Sign up
Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer.
Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality.
We are based in the UK, in Oxford, and in the US, in Philadelphia.
This profile was automatically created. Find out more about Adaptimmune on their company website or check out their opportunities in the opportunities section of this page.